Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PX 104

Next Previous
X
Search
Drug Profile

PX 104

Alternative Names: PX-104

Latest Information Update: 27 Feb 2017

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phenex Pharmaceuticals
  • Class Antihyperlipidaemics; Hepatoprotectants; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-alcoholic fatty liver disease

Most Recent Events

  • 11 Nov 2016 Adverse events and pharmacodynamics data from a phase II trial in Non-alcoholic fatty liver disease presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 07 Feb 2015 Phenex terminates a phase II trial in Non-alcoholic fatty liver disease in Austria (PO) (EudraCT2013-002984-24)
  • 07 Oct 2013 Phase-II clinical trials in Non-alcoholic fatty liver disease in Austria (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top